Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Mais filtros

Intervalo de ano de publicação
Sci Rep ; 9(1): 9986, 2019 07 10.
Artigo em Inglês | MEDLINE | ID: mdl-31292467


Myosin binding protein H-like (MYBPHL) is a protein associated with myofilament structures in atrial tissue. The protein exists in two isoforms that share an identical amino acid sequence except for a deletion of 23 amino acids in isoform 2. In this study, MYBPHL was found to be expressed preferentially in atrial tissue. The expression of isoform 2 was almost exclusively restricted to the atria and barely detectable in the ventricle, arteria mammaria interna, and skeletal muscle. After atrial damage induced by cryo- or radiofrequency ablation, MYBPHL was rapidly and specifically released into the peripheral circulation in a time-dependent manner. The plasma MYBPHL concentration remained substantially elevated up to 24 hours after the arrival of patients at the intensive care unit. In addition, the recorded MYBPHL values were strongly correlated with those of the established biomarker CK-MB. In contrast, an increase in MYBPHL levels was not evident in patients undergoing aortic valve replacement or transcatheter aortic valve implantation. In these patients, the values remained virtually constant and never exceeded the concentration in the plasma of healthy controls. Our findings suggest that MYBPHL can be used as a precise and reliable biomarker to specifically predict atrial myocardial damage.

J Heart Valve Dis ; 23(2): 253-8, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25076560


BACKGROUND AND AIM OF THE STUDY: The Sorin Perceval S (SP) sutureless bioprosthesis was developed as an advancement of conventional biological aortic valve replacement (AVR) with stented bioprostheses, and perhaps also as an alternative to the transcatheter aortic valve implantation (TAVI) procedure, especially for high-risk patients. Herein are described the authors' early results with SP valve replacement, compared to AVR with Carpentier-Edwards Perimount (EP) stented valves. METHODS: Between September 2012 and February 2013, a total of 14 patients was enrolled in a single-center SP study group, and their data were analyzed in a prospective manner. For comparison, 14 patients who received an EP valve replacement during the same period were matched with the SP group, in a retrospective manner. Hemodynamic parameters and clinical outcome were monitored until discharge of the patients in order to analyze the early results of the two groups. RESULTS: The cardiopulmonary bypass (CPB) and aortic cross-clamp (ACC) times needed for AVR with SP valves were significantly shorter than with EP valves. The mean CPB time for SP valve replacement without concomitant procedures was 58.4 +/- 11.0 min, compared to 71.8 +/- 11.3 min in the EP group (p = 0.015), while the mean ACC times were 37.3 +/- 6.8 and 49.1 +/- 11.2 min, respectively (p = 0.006). Permanent pacemaker implantation was required in four patients after SP valve replacement, but in only one patient after EP valve replacement (p = 0.326). The mean transprosthetic peak and mean gradients were 24.8 +/- 5.2 mmHg and 13.3 +/- 3.3 mmHg, respectively, in the SP group, and 19.0 +/- 6.5 mmHg and 10.4 +/- 3.0 mmHg, respectively, in the EP group (p = 0.024 and p = 0.087). The mean valve size was 23.8 +/- 1.3 mm and 23.3 +/- 1.5 mm in the SP and EP groups, respectively. The fall in platelet count after SP valve replacement was 180.4 +/- 79.4 x 10(3)/microl on the first postoperative day (POD), and 114.1 +/- 51.2 x 10(3)/microl with a minimum of 42 x 10(3)/microl and a maximum of 230 x 10(3)/microl at the nadir on POD 2.6 +/- 4.0. The mean minimum values at the nadir corresponded to 40% of the initial preoperative value. CONCLUSION: The sutureless SP bioprosthesis seems to represent a good alternative to conventional stented bioprostheses, especially in older patients with a high-risk profile, and particularly if concomitant surgical procedures are planned.

Insuficiência da Valva Aórtica/cirurgia , Estenose da Valva Aórtica/cirurgia , Valva Aórtica/cirurgia , Bioprótese , Implante de Prótese de Valva Cardíaca/instrumentação , Próteses Valvulares Cardíacas , Idoso , Idoso de 80 Anos ou mais , Animais , Valva Aórtica/fisiopatologia , Insuficiência da Valva Aórtica/fisiopatologia , Estenose da Valva Aórtica/diagnóstico , Estenose da Valva Aórtica/fisiopatologia , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/terapia , Estimulação Cardíaca Artificial , Ponte Cardiopulmonar , Feminino , Alemanha , Implante de Prótese de Valva Cardíaca/efeitos adversos , Hemodinâmica , Humanos , Masculino , Estudos Prospectivos , Desenho de Prótese , Reoperação , Estudos Retrospectivos , Suínos , Fatores de Tempo , Resultado do Tratamento
São Paulo; Antroposófica; 1985. 101 p.
Monografia em Português | LILACS, HomeoIndex - Homeopatia | ID: biblio-909986
São Paulo; Antroposófica; 1985. 101 p.
Monografia em Português | HomeoIndex - Homeopatia | ID: hom-11617
São Paulo;; Antroposófica; 1984. 79 p.
Monografia em Português | LILACS, HomeoIndex - Homeopatia | ID: biblio-909991
São Paulo; Antroposófica; 1984. 79 p.
Monografia em Português | HomeoIndex - Homeopatia | ID: hom-11616
Br. homoeopath. j ; 65(3): 138-145, july 1976.
Artigo em Inglês | HomeoIndex - Homeopatia | ID: hom-6358